MiStent SES shows benefits for CAD - Micell Tech
The DESSOLVE I and II clinical trials using the MiStent SES (sirolimus eluting stent), from Micell Technologies, in patients with Coronary Artery Disease shows that rapid polymer absorption within three months coupled with drug delivery profile up to nine months provides for excellent healing.
The DESSOLVE I trial demonstrated minimal progression of late lumen loss between eight and 18 months follow-up, with no target lesion MACE events through two years. The DESSOLVE II randomized trial two-year MACE rate was 6.7% for MiStent and 13.3% for the Endeavor DES control group. There were no probable or definite stent thromboses related to MiStent SES use in either trial through two years.
Detailed serial IVUS, angiographic, and OCT imaging through 18 months in DESSOLVE I and angiographic and OCT imaging in conjunction with endothelial function testing in DESSOLVE II demonstrated excellent healing, effective suppression of neointimal hyperplasia with maintenance of normal endothelial function, and a sustained safety profile. Data were presented at the Cardiovascular Research Technologies (CRT) Conference.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins